Australia's Imugene surges after US FDA grants product Fast Track status
09/06/2026 06:23
BUZZ-Australia's Imugene surges after US FDA grants product Fast Track status ** Shares of Imugene IMU.AX rise as much as 14.1% to A$0.105, their biggest intraday pct gain since May 26
** Cell therapy co says U.S. Food and Drug Administration grants Fast Track Designation to azer-cel (azercabtagene zapreleucel)
** Fast Track Designation for two indications: relapsed or refractory Chronic Lymphocytic Leukaemia/ Small Lymphocytic Lymphoma (CLL/SLL) and relapsed or refractory Marginal Zone Lymphoma (MZL)
** Azer-cel an off-the-shelf, CD19-directed CAR T-cell therapy engineered to overcome logistical constraints of autologous CAR T therapies, co says
** YTD, IMU shares down 74.3%
(Reporting by Nichiket Sunil in Bengaluru)
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement